Website
News25/Ratings0
News · 26 weeks46+300%
2025-10-262026-04-19
Mix2490d
- Market16(67%)
- Insider5(21%)
- SEC Filings2(8%)
- Other1(4%)
Latest news
25 items- NEWSIGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward CompletionBehavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study POTOMAC, MD / ACCESS Newswire / April 22, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced the addition of Kerwin Medical Center in Dallas, Texas as a clinical site in the Company's Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's disease. The Company recently reported approximately 80% enrollment in CALMA and continues to advance toward enrollment completion. The addition comes as the CALMA trial advances through its final phase of en
- SECIGC Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - IGC Pharma, Inc. (0001326205) (Filer)
- NEWSIGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in DementiaAuthorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completion POTOMAC, MD / ACCESS Newswire / April 20, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that on April 9, 2026, it received authorization in Colombia to synthesize, formulate, and conduct development activities involving psilocybin at its research and development facility in Bogotá. The authorization, granted under the oversight of the Fondo Nacional de Estupefacientes (FNE), provides IGC Pharma with a regulated capability to work wit
- NEWSIGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data ReadoutPOTOMAC, MD / ACCESS Newswire / April 14, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company") today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease.This milestone represents a significant step in advancing the program toward enrollment completion, expected in mid-2026, and positions the Company to progress toward database lock and topline results. Enrollment progress across the Company's US and Canadian clinical network continues to support consistent execution as the study enters its final phase.Approaching a Defined Clinical Catalyst"Reaching 80% enrollment marks an i
- NEWSAscendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming CatalystsPOTOMAC, MD / ACCESS Newswire / April 8, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company with its lead program currently in a Phase 2 CALMA clinical trial evaluating IGC-AD1 for Alzheimer's-related agitation today announced that Ascendiant Capital Markets has issued an updated equity research report on the Company, raising its price target to $5.25 per share.The research report entitled, "Reports Q3. We believe more positive clinical data and progress in 2026 to be strong catalysts for stock. Raising P/T to $5.25" can be obtained directly from Ascendiant Capital Markets Link.All reports on IGC Pharma prepared by analysts represent the views
- NEWSIGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's DiseasePOTOMAC, MD / ACCESS Newswire / April 7, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing innovative treatments for Alzheimer's disease, today announced the activation of a new clinical trial site at Tandem Clinical Research A Prolerity Network Site in Metairie, Louisiana, for the Company's ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation in Alzheimer's dementia.The site, located at 3901 Houma Blvd., Suite 500, Metairie, LA 70006, is led by Principal Investigator Dr. Angela Traylor, an experienced neurologist and psychiatrist who has served as both Principal Investigator and Sub-Investigator across multiple ne
- INSIDERSEC Form 4 filed by Prins Richard K4 - IGC Pharma, Inc. (0001326205) (Issuer)
- INSIDERSEC Form 4 filed by Mukunda Ram4 - IGC Pharma, Inc. (0001326205) (Issuer)
- INSIDERSEC Form 4 filed by Moran James P4 - IGC Pharma, Inc. (0001326205) (Issuer)
- INSIDERSEC Form 4 filed by Grimaldi Claudia4 - IGC Pharma, Inc. (0001326205) (Issuer)
- SECIGC Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - IGC Pharma, Inc. (0001326205) (Filer)
- NEWSIGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor AwarenessPOTOMAC, MD / ACCESS Newswire / March 30, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced a strategic 12-part national media partnership with New to The Street, a leading financial media platform known for its integrated investor engagement and national television distribution.The collaboration is designed to enhance IGC Pharma's visibility across both institutional and retail investor audiences through a coordinated, multi-channel media strategy. The campaign will include long-form televised interviews, national television commercial distribution, digital amplification, and h
- NEWSIGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025- Strategic Pivot to Pure-Play Biotech -POTOMAC, MD / ACCESS Newswire / March 19, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced the filing of its Report on Form 10-KT with the U.S. Securities and Exchange Commission ("SEC") for the nine months ended December 31, 2025.The Company recently changed its fiscal year-end from March 31 to December 31 to better align its reporting with clinical and industry cycles. The current report reflects a nine-month transition period defined by clinical acceleration, the successful divestiture of non-core assets, and international validation o
- SECSEC Form 10-KT filed by IGC Pharma Inc.10-KT - IGC Pharma, Inc. (0001326205) (Filer)
- NEWSIGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026POTOMAC, MD / ACCESS Newswire / March 18, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced it will demonstrate its Agentic Harmonization Assistant ("AHA"), an artificial intelligence platform designed to automate the integration and analysis of complex biomedical datasets, at the Alzheimer's & Parkinson's Diseases Conference (ADPD) 2026.The demonstration will take place in collaboration with the Alzheimer's Disease Data Initiative (ADDI), a global data-sharing platform supported by Gates Ventures and leading research institutions focused on accelerating discoveries in neurodege
- NEWSIGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's ResearchPOTOMAC, MD / ACCESS Newswire / February 26, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced the filing of utility patent applications covering the architectural framework of its Agentic Harmonization Assistant ("AHA"), an internally developed AI-based data harmonization system.IGC is developing AHA to support the standardization of heterogeneous Alzheimer's disease datasets, which often vary significantly in schema definitions, variable encodings, and data structures. These inconsistencies can limit cross-cohort analysis and slow both clinical research and AI model developmen
- NEWSIGC Pharma Notes Updated Research Coverage from Ascendiant Capital MarketsPOTOMAC, MARYLAND / ACCESS Newswire / February 24, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), today announced that Ascendiant Capital Markets has issued an updated equity research report covering the Company. According to the Ascendiant Capital Markets, the report raises its price target to $5.00 per share.All statements, opinions, estimates, projections, and conclusions contained in analyst reports represents the views of the respective analysts and are not those of IGC Pharma. By referring to these analysts or distributing their opinions, IGC does not in any way commit itself to the validity of such information, conclusions, or recommendations.A copy of the updated report
- NEWSIGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial- Practice integrated neurology network expands enrollment capacity -POTOMAC, MARYLAND / ACCESS Newswire / February 23, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), today announced the addition of Visionary Investigators Network ("VIN") as a clinical research site participating in the Company's Phase 2 CALMA trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer's disease dementia.VIN operates clinical research programs embedded within established private neurology practices, providing access to well-characterized patient populations while maintaining continuity of clinical care. IGC Pharma believes this practice-integrated model supports efficient
- NEWSIGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment AdvancesPOTOMAC, MD / ACCESS Newswire / February 17, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), today announced that the Canadian Intellectual Property Office ("CIPO") has issued a Notice of Allowance covering the proprietary composition underlying IGC-AD1, the Company's Phase 2 clinical stage program for agitation associated with Alzheimer's disease. With this allowance, patent No. 3,095,729, titled "Method and Composition for Treating CNS Disorders", IGC has secured composition protection for IGC-AD1 across key North American jurisdictions, reinforcing the long-term exclusivity around the formulation as the Phase 2 CALMA trial advances toward enrollment completion. The protection
- NEWSIGC Pharma to Participate in Fireside Chat With Ascendiant Capital MarketsPOTOMAC, MD / ACCESS Newswire / February 12, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Wednesday, February 18, 2026, at 1:00 p.m. ET.IGC Pharma's management will discuss recent clinical progress in its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease, including enrollment momentum and regulatory developments. The discussion will also cover advancements in the Company's AI-driven precision medicine platform and progress across its broader pipeline of disease-modifying Alzheimer's candidates. Ma
- NEWSIGC Pharma Announces Equity Research Update by Alliance Global PartnersPOTOMAC, MARYLAND / ACCESS Newswire / February 10, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), today announced that Alliance Global Partners ("AGP") has published an updated equity research report covering the Company.The report reiterates a Buy rating and includes a price target of $3.00 per share. All statements, opinions, estimates, projections, and conclusions contained in analyst reports represent the views of the respective analysts and are not those of IGC Pharma. IGC does not endorse, adopt, or guarantee the accuracy or completeness of any analyst report and undertakes no obligation to update or correct the information.A copy of the report may be obtained from AGP: L
- NEWSIGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center- Adds world renowned GNA site to broaden genetic diversity and strengthen path toward 2026 data catalyst -POTOMAC, MARYLAND / ACCESS Newswire / February 9, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company") today announced the expansion of its Phase 2 CALMA trial for IGC-AD1 into Colombia, South America, through the addition of Grupo de Neurociencias de Antioquia ("GNA").This expansion marks a pivotal operational milestone as IGC enters a region internationally recognized for its unique, genetically linked Alzheimer's population. The GNA site is the latest addition to a clinical network that now spans 23 active sites across 26 locations in the United States and Canada.CALMA is a ra
- INSIDERCEO Mukunda Ram converted options into 50,000 shares (SEC Form 4)4 - IGC Pharma, Inc. (0001326205) (Issuer)
- NEWSIGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's AgitationPOTOMAC, MARYLAND / ACCESS Newswire / February 2, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), today reported it has reached approximately 70% of planned patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer's disease.The Company has approximately 23 active sites across 26 locations, and enrollment is progressing across this clinical network. IGC expects to complete enrollment by mid-2026. The Company believes this milestone meaningfully reduces the primary operational risk for the trial and positions CALMA to progress toward database lock and topline results."Reaching ~70% enrollment reflects improv
- NEWSIGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York- Multi-Specialty CNS Research Center Strengthens Trial Execution and Patient Diversity in Alzheimer's Agitation Study -POTOMAC, MD / ACCESS Newswire / January 22, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging Artificial Intelligence ("AI") to develop innovative treatments for Alzheimer's disease, today announced the addition of Integrative Clinical Trials, LLC, located in Brooklyn, New York, as a new clinical site participating in the Company's Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer's disease.Integrative Clinical Trials is a clinical research center conducting